Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Jazz Pharmaceuticals plc

Get SEC filing alerts via email and in your feed for Jazz Pharmaceuticals plc

JAZZ

Jazz Pharmaceuticals plc

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases in neuroscience and oncology. Its core products include therapies for sleep disorders, epilepsy, and cancer, such as Xywav, Epidiolex, Rylaze, Zepzelca, and Ziihera. The company emphasizes innovative research, strategic acquisitions, and efficient global operations to address high unmet medical needs and deliver long-term value.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Jazz Pharmaceuticals plc

1
1
Jazz Pharmaceuticals plc Jazz Pharmaceuticals Reports 19% Revenue Growth to $1.0689 Billion in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Jazz Pharmaceuticals plc Jazz Pharmaceuticals Reports $4.27 Billion in Revenue for 2025, Highlights Strategic Acquisitions

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Jazz Pharmaceuticals plc Jazz Pharmaceuticals Reports 7% Revenue Growth to $1.126 Billion in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Jazz Pharmaceuticals plc Jazz Pharmaceuticals Reports Q2 2025 Financial Results with $1.045 Billion Revenue

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Jazz Pharmaceuticals plc Jazz Pharmaceuticals Reports Q1 2025 Financial Results with Revenue of $897.8 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Jazz Pharmaceuticals plc Jazz Pharmaceuticals Reports 9% Revenue Growth in Q3 2024, Net Income Up 46%

Via official filing (AI summary) | over 1 year ago | 0 comments